BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
$74.95 4.22 (5.9664%)
Analysed BRIDGEBIO PHARMA INC (BBIO:NASDAQ) News Sources
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
21-10-2026
yahoo.com
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
22-10-2026
yahoo.com
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
29-10-2026
yahoo.com
BridgeBio Pharma: Q3 Earnings Snapshot
29-10-2026
yahoo.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
29-10-2026
yahoo.com
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
29-10-2026
yahoo.com
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
30-10-2026
marketbeat.com
BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary
30-10-2026
moby.co
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
30-10-2026
fool.com
BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says
30-10-2026
yahoo.com
What is the current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is $74.95.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is $4.22.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is 5.9664%.
What is the most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is 50 out of 100.
What is the most recent average sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is .
SEC-8K** Filing Available For BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.